SYNAPTIFLORA
Revolutionizing Drug Development with Microbiome Insights
Our
Story
"The moment you have a personal connection to a cause, it becomes part of who you are and what you fight for."
Melinda Gates
Synaptiflora started as a personal journey between two friends—one from AI and the other from biology—both navigating the challenges of chronic health conditions.
​
Experiencing the slow, costly process of drug development firsthand, we were struck by how long patients have to wait for new therapies.
​
Driven by a shared vision and the desire to make a difference, we set out to change that.
​
The Challenges of Drug Development
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
Problem:
Microbiome Data
Clinical Data
Genomic Data
Microbiome Data is missing in
Drug Development
Pharmaceutical drug development is broken. Nearly 1 million compounds enter the pipeline, and only one makes it through—with 10% success rate. But it gets worse: even that one approved drug, which takes 10 years and $4 billion to develop, fails to work in 60% of patients. And yet, in oncology, this is still considered a good result. We know that microbiome dramatically affects drug response and can be answer to the problem, yet microbiome data remains absent from most clinical development.
Our Vision
We believe that humanity is on the brink of a microbiome-driven revolution that will transform healthcare and unlock new frontiers in medicine. We are passionate about building the artificial intelligence platforms that will lead us into this new era of personalized therapeutics and Pharma 4.0.
Our Mission
​
-
Raise drug efficacy rates from 40% to 60–80%
-
Cut trial timelines by 2x
-
Become the foundational technology for microbiome-based clinical development globally
TECHNOLOGY
Innovative Solutions for Pharma 4.0
At the heart of our technology is SynaptiCore, a cutting-edge AI foundation model built on curated dataset that integrates microbiome composition, metabolomics, and host interactions. SynaptiCore deciphers the complex relationships between the microbiome, host genetics, and metabolic pathways, delivering unparalleled insights.
Our Scalable SaaS Platform transforms SynaptiCore into specialized, disease-specific tools tailored for pharmaceutical R&D, drug development, and clinical trials. These tools empower researchers and clinicians with actionable insights for patient stratification, efficacy prediction, and trial optimization—accelerating the journey to effective therapies.
From colorectal cancer to neurology and immunology, each disease-specific package enhances SynaptiCore’s capabilities, creating a dynamic, continuously improving ecosystem for precision medicine.
